These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 7576913)

  • 41. Positioning of positively charged residues in the V3 loop correlates with HIV type 1 syncytium-inducing phenotype.
    Bhattacharyya D; Brooks BR; Callahan L
    AIDS Res Hum Retroviruses; 1996 Jan; 12(2):83-90. PubMed ID: 8834457
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Molecular analysis of the principal neutralization epitope (V3 loop) of human immunodeficiency virus type 1 in Argentina].
    Gómez Carrillo M; Piccardo C; Libonatti O
    Rev Argent Microbiol; 1992; 24(2):91-101. PubMed ID: 1298019
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The anti-HIV activity of ADS-J1 targets the HIV-1 gp120.
    Armand-Ugón M; Clotet-Codina I; Tintori C; Manetti F; Clotet B; Botta M; Esté JA
    Virology; 2005 Dec; 343(1):141-9. PubMed ID: 16168454
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Structural features of HIV envelope defined by antibody escape mutant analysis.
    D'Costa S; Slobod KS; Webster RG; White SW; Hurwitz JL
    AIDS Res Hum Retroviruses; 2001 Aug; 17(12):1205-9. PubMed ID: 11522189
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lack of correlation between V3 amino acid sequence and syncytium-inducing capacity of some HIV type 1 isolates.
    Sabri F; Chiodi F; Fenyö EM
    AIDS Res Hum Retroviruses; 1996 Jul; 12(10):855-8. PubMed ID: 8798969
    [No Abstract]   [Full Text] [Related]  

  • 46. Inhibition of entry of HIV into cells by poly(A).poly(U).
    Krust B; Callebaut C; Hovanessian AG
    AIDS Res Hum Retroviruses; 1993 Nov; 9(11):1087-90. PubMed ID: 8312051
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Three-dimensional structure-activity analysis of a series of porphyrin derivatives with anti-HIV-1 activity targeted to the V3 loop of the gp120 envelope glycoprotein of the human immunodeficiency virus type 1.
    Debnath AK; Jiang S; Strick N; Lin K; Haberfield P; Neurath AR
    J Med Chem; 1994 Apr; 37(8):1099-108. PubMed ID: 8164251
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule.
    Fouchier RA; Groenink M; Kootstra NA; Tersmette M; Huisman HG; Miedema F; Schuitemaker H
    J Virol; 1992 May; 66(5):3183-7. PubMed ID: 1560543
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dextran sulfate and other polyanionic anti-HIV compounds specifically interact with the viral gp120 glycoprotein expressed by T-cells persistently infected with HIV-1.
    Schols D; Pauwels R; Desmyter J; De Clercq E
    Virology; 1990 Apr; 175(2):556-61. PubMed ID: 1691563
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CD4-derived peptide and sulfated polysaccharides have similar mechanisms of anti-HIV activity based on electrostatic interactions with positively charged gp120 fragments.
    Meshcheryakova D; Andreev S; Tarasova S; Sidorova M; Vafina M; Kornilaeva G; Karamov E; Khaitov R
    Mol Immunol; 1993 Aug; 30(11):993-1001. PubMed ID: 8102473
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Anti-HIV type 1 properties of chemically modified heparins with diminished anticoagulant activity.
    Lopalco L; Ciccomascolo F; Lanza P; Zoppetti G; Caramazza I; Leoni F; Beretta A; Siccardi AG
    AIDS Res Hum Retroviruses; 1994 Jul; 10(7):787-93. PubMed ID: 7986584
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Anti-HIV-1 activity of chemically modified heparins: correlation between binding to the V3 loop of gp120 and inhibition of cellular HIV-1 infection in vitro.
    Rider CC; Coombe DR; Harrop HA; Hounsell EF; Bauer C; Feeney J; Mulloy B; Mahmood N; Hay A; Parish CR
    Biochemistry; 1994 Jun; 33(22):6974-80. PubMed ID: 7911328
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Additive effect of tunicamycin and dextran sulfate on the binding of monoclonal antibody to the V2 domain of the envelope glycoprotein 120 of human immunodeficiency virus type 1.
    Jagodzinski PP; Trzeciak WH
    Biomed Pharmacother; 2001 Jul; 55(6):308-12. PubMed ID: 11478581
    [TBL] [Abstract][Full Text] [Related]  

  • 54. RhoA-derived peptide dimers share mechanistic properties with other polyanionic inhibitors of respiratory syncytial virus (RSV), including disruption of viral attachment and dependence on RSV G.
    Budge PJ; Li Y; Beeler JA; Graham BS
    J Virol; 2004 May; 78(10):5015-22. PubMed ID: 15113882
    [TBL] [Abstract][Full Text] [Related]  

  • 55. An efficient system for site-directed mutagenesis to make various mutants of the env gene of human immunodeficiency virus type 1.
    Shimizu N; Hoshino H
    FEBS Lett; 1998 Jul; 430(3):333-7. PubMed ID: 9688566
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Human immunodeficiency virus glycoprotein gp120 as the primary target for the antiviral action of AR177 (Zintevir).
    Esté JA; Cabrera C; Schols D; Cherepanov P; Gutierrez A; Witvrouw M; Pannecouque C; Debyser Z; Rando RF; Clotet B; Desmyter J; De Clercq E
    Mol Pharmacol; 1998 Feb; 53(2):340-5. PubMed ID: 9463493
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The bicyclams, a new class of potent human immunodeficiency virus inhibitors, block viral entry after binding.
    De Vreese K; Reymen D; Griffin P; Steinkasserer A; Werner G; Bridger GJ; Esté J; James W; Henson GW; Desmyter J; Anné J; De Clercq I
    Antiviral Res; 1996 Mar; 29(2-3):209-19. PubMed ID: 8739600
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inhibitory effect of dextran sulfate and heparin on the replication of human immunodeficiency virus (HIV) in vitro.
    Ito M; Baba M; Sato A; Pauwels R; De Clercq E; Shigeta S
    Antiviral Res; 1987 Jul; 7(6):361-7. PubMed ID: 2445284
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro.
    Baba M; Pauwels R; Balzarini J; Arnout J; Desmyter J; De Clercq E
    Proc Natl Acad Sci U S A; 1988 Aug; 85(16):6132-6. PubMed ID: 2457906
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sulphated polysaccharides exert anti-HIV activity at differing sites.
    Harrop HA; Rider CC; Coombe DR
    Biochem Soc Trans; 1992 May; 20(2):163S. PubMed ID: 1397551
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.